AVITA Medical Inc. (RCEL)
10.07
0.00 (0.00%)
Apr 28, 2025, 1:31 PM - Market open
0.00% (1D)
| Bid | 10.04 |
| Market Cap | 266.2M |
| Revenue (ttm) | 58.88M |
| Net Income (ttm) | -50.8M |
| EPS (ttm) | -2.39 |
| PE Ratio (ttm) | -4.21 |
| Forward PE | 17.33 |
| Analyst | Buy |
| Ask | 10.1 |
| Volume | 47,810 |
| Avg. Volume (20D) | 198,603 |
| Open | 10.06 |
| Previous Close | 10.07 |
| Day's Range | 10.01 - 10.24 |
| 52-Week Range | 6.90 - 14.16 |
| Beta | 1.60 |
About RCEL
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a ...
Industry Medical - Devices
Sector Healthcare
IPO Date May 14, 2012
Employees 260
Stock Exchange NASDAQ
Ticker Symbol RCEL
Website https://www.avitamedical.com
Analyst Forecast
According to 4 analyst ratings, the average rating for RCEL stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 73.78% from the latest price.
Stock ForecastsNext Earnings Release
AVITA Medical Inc. is scheduled to release its earnings on May 8, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+20.39%
AVITA Medical shares are trading higher. The compa...
Unlock content with
Pro Subscription
3 months ago
-36.42%
Avita Medical shares are trading lower after Lake Street cut its price target on the stock from $20 to $14.
